First Pediatric MVID Patient Enters Pivotal Crofelemer Trial Extension
JAGX sits 33% above its 52-week low of $2.53.
Summary
Jaguar Health announced that the first pediatric patient has entered the treatment-only extension phase of its pivotal crofelemer powder trial for Microvillus Inclusion Disease (MVID). This marks a significant step forward in the clinical development of a key product for the company. While the headline also noted the conversion of $22.7 million in royalty interests to Series Q preferred stock, this financial event was previously reported in an 8-K filing on May 19th. For Jaguar Health, a company facing severe financial distress, progress in pivotal clinical trials is crucial for future regulatory submissions and potential long-term revenue generation. Investors should monitor further trial enrollment updates, data readouts, and the eventual path to an NDA submission.
At the time of this announcement, JAGX was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $2.53 to $241.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.